Key Points
- CFO Scott Ullem sold 13,000 shares of Edwards Lifesciences on March 11 at an average price of $84.92 for about $1.104 million, cutting his ownership by 24.67% to 39,699 shares (approx. $3.37 million).
- Edwards missed EPS estimates (reported $0.58 vs. $0.62 expected) while beating revenue ($1.57B vs. $1.54B), set Q1 2026 guidance of $0.700–$0.760 EPS, and carries a consensus analyst rating of "Moderate Buy" with an average price target of $96.14.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 1,019 shares of the firm's stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the completion of the sale, the vice president directly owned 33,934 shares of the company's stock, valued at $2,897,284.92. The trade was a 2.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Edwards Lifesciences Stock Down 0.5%
NYSE:EW traded down $0.45 during mid-day trading on Thursday, hitting $84.64. 444,603 shares of the company's stock traded hands, compared to its average volume of 4,542,033. The company has a fifty day moving average of $82.49 and a 200 day moving average of $81.55. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The company has a market capitalization of $49.16 billion, a P/E ratio of 46.22, a P/E/G ratio of 2.24 and a beta of 0.93.
Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts' consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion for the quarter, compared to analysts' expectations of $1.54 billion. During the same quarter in the previous year, the firm posted $0.59 EPS. Edwards Lifesciences's revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in Edwards Lifesciences by 7.0% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company's stock valued at $10,719,000 after acquiring an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Edwards Lifesciences by 13.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company's stock worth $6,706,000 after purchasing an additional 10,078 shares during the last quarter. Atlantic Union Bankshares Corp raised its stake in Edwards Lifesciences by 2,240.9% during the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company's stock worth $925,000 after purchasing an additional 11,384 shares during the period. OMERS ADMINISTRATION Corp boosted its holdings in Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company's stock valued at $3,481,000 after purchasing an additional 21,950 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock valued at $1,478,425,000 after buying an additional 1,423,365 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
EW has been the subject of several research reports. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 12th. TD Cowen upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Friday, January 9th. Barclays reaffirmed an "overweight" rating and set a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. Finally, JPMorgan Chase & Co. upgraded Edwards Lifesciences from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $90.00 to $100.00 in a research note on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $96.14.
Get Our Latest Stock Report on Edwards Lifesciences
About Edwards Lifesciences
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
